Abstracts tagged "interferons and Sjogren’s syndrome"

Abstract Number: 1902 • 2019 ACR/ARP Annual Meeting
Systems Biology in 874 Patients with Primary Sjögren’s Syndrome Indicates the Predominant Role of Interferon Alpha Compared to Interferon Gamma, Its Association with Systemic Complications, and a New Aspect of the Genetic Contribution of HLA
Pierre Bost ¹, Xavier Mariette ², Vincent Bondet ³, Alba Llibre ¹, Céline Posseme ³, Bruno Charbit ³, Christian Thorball ⁴, Roland Jonsson ⁵, Chris Lessard ⁶, Renaud Felten ⁷, Fai Ng ⁸, K Silvis ⁹, Lucienne Chatenoud ¹⁰, Hélène Dumortier ¹¹, Jacques Fellay ⁴, Karl A Brostadt ¹², Silke Appel ⁵, Jessica R Tarn ⁸, Lluis Quintana-Murci ³, Michael Minguenau ¹³, Nicolas Meyer ¹⁴, Darragh Duffy ¹, Benno Schwikowski ¹ and Jacques-Eric Gottenberg¹⁵, ¹PASTEUR, PARIS, France, ²Université Paris-Sud, Paris, France, Paris, Centre, France, ³PASTEUR, PARIS, Centre, France, ⁴School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland, ⁵University of Bergen, Bergen, Norway, ⁶ORMF, Oklahoma City, ⁷Strasbourg Unviersity Hospital, Strasbourg, Alsace, France, ⁸Newcastle Hospital, Newcastle, United Kingdom, ⁹ORMF, Oklahoma, ¹⁰Necker Hospital, Paris, France, ¹¹IBMC, Strasbourg, Alsace, France, ¹²Universiy of Bergen, Bergen, Norway, ¹³Biogen, Boston, ¹⁴Strasbourg University Hospital, STRASBOURG, France, ¹⁵Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Primary Sjögren’s syndrome (pSS) is the second most frequent systemic autoimmune disease affecting 0.1% of the general population. No specific immunomodulatory drug has demonstrated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].